CartiHeal
- Industry
- Medical Devices
- Founded Year
- 2009
- Headquarters
- 17 Atir Yeda, Kfar Saba, Israel
- Employee Count
- 104
Key People
-
Nir Altschuler - Founder & CEO
Email: n*******@cartiheal.com
- Amir Goren - VP, Operations
- Dror Robinson - Medical Director
- Rikki Halevy - QA & RA Manager
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team, led by founder and CEO Nir Altschuler, has extensive experience in the medical device field, contributing to the company's innovative approach.
A strong leadership team with multiple successful ventures in the MedTech sector significantly increases the likelihood of successful product development and market penetration.
- Clinical Need
-
Aspect: Very Strong
Summary: CartiHeal addresses a significant unmet need in treating cartilage and osteochondral defects, offering a novel solution for patients with limited options.
By targeting a substantial patient population with limited existing treatments, CartiHeal's product fulfills a critical clinical need, enhancing its market potential.
- Competition
-
Aspect: First mover
Summary: CartiHeal's Agili-C implant offers a unique, cell-free solution for cartilage repair, distinguishing it from existing treatments.
Being a first mover with a novel technology provides a competitive edge, allowing the company to establish market leadership before competitors develop similar solutions.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of the Agili-C implant involves predictable technical challenges, leveraging existing knowledge in biocompatible materials and implant design.
Predictable technical challenges allow for more accurate planning and resource allocation, reducing development risks and timelines.
- Patent
-
Aspect: Very Strong
Summary: CartiHeal holds robust patents protecting its Agili-C implant technology, providing a strong intellectual property position.
A very strong patent position safeguards the company's innovations, deterring competitors and potentially increasing valuation.
- Financing
-
Aspect: Strategics
Summary: CartiHeal has secured substantial funding from strategic investors, including Bioventus and Johnson & Johnson Innovation, culminating in its acquisition by Smith & Nephew.
Strategic financing and acquisition by a major industry player like Smith & Nephew provide not only capital but also market expertise and distribution channels, accelerating commercialization.
- Regulatory
-
Aspect: 510k/PMA + Reimbursement
Summary: The Agili-C implant received FDA Premarket Approval (PMA) in March 2022, with reimbursement pathways established, facilitating market entry.
Achieving FDA approval and securing reimbursement are critical milestones that significantly reduce barriers to market entry and adoption.
Opportunity Rollup
- Odds of Success
- 4.8
- Peak Market Share
- 6.9
- Segment CAGR
- 3.0%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Cartilage Repair Implants
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.34 |
| 2 | 1.03 |
| 3 | 2.42 |
| 4 | 4.83 |
| 5 | 6.90 |
Key Takeaway
CartiHeal's innovative Agili-C implant addresses a significant clinical need in cartilage repair, supported by strong leadership, robust patents, strategic financing, and favorable industry trends, positioning the company for substantial market success.